<DOC>
	<DOCNO>NCT00888745</DOCNO>
	<brief_summary>This Phase I multicenter study conduct United States Europe .</brief_summary>
	<brief_title>A Study Safety Pharmacokinetics PRO283698 Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>RA diagnose accord American College Rheumatology ( ACR ) Female patient pregnant , plan become pregnant study , breastfeed Clinically significant abnormal ECG History anaphylactic reaction Positive hepatitis C antibody hepatitis B surface antigen Positive serology human immunodeficiency virus ( HIV ) quantitative polymerase chain reaction A history autoimmune disease RA ( secondary Sjogren syndrome ) Significant systemic involvement RA , include vasculitis , pulmonary fibrosis , Felty syndrome Malignancy , prior malignancy , nonmelanoma skin cancer , cervical carcinoma situ resect Recent administration live , attenuated vaccine , anticipation live attenuated vaccine require study within 60 day last dose Concomitant therapy biologic agent Recent exposure investigational agent Any current recent sign symptom infection require parenteral antibiotic administration Hospitalization clinically relevant event within 4 week prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>RA</keyword>
</DOC>